Peritoneal Dialysis Update — Oct 29, 2026
Generated Oct 30, 2026 · 12:08
The latest research on this topic, summarized for clinicians.
If the audio fails to play, refresh the page to renew the link.
Get this every week in your podcast app — free.
New research episodes land in your feed automatically — listen on your commute.
Papers in this briefing
- 01
Association of Estimated GFR at the Time of Peritoneal Dialysis Catheter Insertion With Dialysis-Related Complications.
In 1,537 patients, each 1 ml/min lower eGFR at catheter insertion carried 10% higher complication risk, and starting PD within 30 days of insertion raised risk (aHR 3.15), favoring earlier placement.
American Journal of Kidney Diseases · 2026
From the briefingCatheter access is where most early technique failure begins, and three papers this period look at it from insertion through to salvage. The most provocative is a North American registry analysis in the American Journal of Kidney Diseases from Dhoot and colleagues [1]. They asked whether symptom-driven dialysis initiation, which current guidelines endorse, leaves patients getting catheters too late and starting too soon. Among 1,537 catheter insertions, about two thirds of patients had an eGFR of 9 or below at placement. The headline comparison was flat: early complications ran at roughly a fifth in both groups, with no statistically significant difference. Within the lower-function group, though, each one-point drop in eGFR carried about a ten percent higher complication risk. Starting dialysis within thirty days of insertion roughly tripled the risk of complications, which were mostly flow problems, leaks and pain. Conversion to haemodialysis did not differ. There is an internal tension here. The dichotomous comparison found nothing, and the signal emerges only in a continuous within-group model. The design is retrospective, the eGFR values were not standardized, function was not measured at actual dialysis start, and pre-dialysis care and embedded catheters were not accounted for. The authors read this as support for earlier insertion and a longer break-in period. The evidence is observational and hypothesis-generating rather than settled, and it sits awkwardly against guidance that has not changed.
Written by AI from the published abstract, for healthcare professionals. Not medical advice; check the paper before acting on it.
- 02
Initiating Patients on Peritoneal Dialysis Compared with In-Centre Haemodialysis in the United Kingdom: A Cost-Utility and Budget Impact Analysis.
Modelling showed initiating on PD instead of in-centre HD yielded 0.15 extra QALYs and £19,728 savings per patient, and increased PD uptake would save about £220 million over 5 years.
PharmacoEconomics - open · 2026
From the briefingFinally, two papers approach the choice of peritoneal dialysis itself, one from the health system and one from the patient's chair, and they do not tell the same story. In PharmacoEconomics Open, Li and colleagues modelled lifetime outcomes for incident patients in the United Kingdom National Health Service [2]. Starting on peritoneal dialysis rather than in-centre haemodialysis gained a small amount of quality-adjusted life and saved roughly twenty thousand pounds per patient. That makes it dominant across sensitivity analyses. Their budget model projected savings of about 220 million pounds over five years if prevalence reached twenty percent. This is a Markov model built on registry data, so its conclusions inherit the selection that shapes who currently receives peritoneal dialysis. The abstract does not describe funding or conflicts of interest, which matters for an analysis of this kind.
Written by AI from the published abstract, for healthcare professionals. Not medical advice; check the paper before acting on it.
- 03
Peritoneal catheter fixation versus nonfixation in open surgery: A meta-analysis.
Across 1,275 patients, catheter fixation sharply reduced displacement (OR 0.08) without raising infection or other complications, at the cost of about 4 minutes more operating time.
Medicine · 2026
From the briefingOnce the catheter goes in, a meta-analysis in Medicine from Tang and colleagues asks whether fixing it in place during open surgery is worth the effort [3]. Across thirteen studies and about 1,275 patients, fixation cut the odds of catheter displacement by more than ninety percent. It did so without measurably increasing infection, bleeding, hernia, infusion pain or omental wrapping, at a cost of about four extra minutes of operating time. Fixation did nothing for malfunction without displacement, which matters. The authors conclude fixation is safe and effective. Several of the pooled outcomes rest on very few events, however, and the included studies appear to be largely smaller trials and cohorts of variable quality, so the displacement finding is the robust part.
Written by AI from the published abstract, for healthcare professionals. Not medical advice; check the paper before acting on it.
- 04
Peritoneal dialysis catheter dysfunction: when can the catheter be rescued?
Catheter dysfunction should be managed by mechanism, from treating constipation and fibrin to fluoroscopic manipulation or laparoscopic revision, with a written rescue pathway to limit temporary hemodialysis and technique failure.
Current opinion in nephrology and hypertension · 2026
From the briefingThat distinction between position and function is exactly where a review in Current Opinion in Nephrology and Hypertension, by McMonagle and Jain, picks up [4]. They argue that dysfunction is too often handled as generic access failure when the response should follow the mechanism. Their sequence starts with excluding infection and acute abdominal pathology, then treating constipation and fibrin, with early abdominal radiography. Fluoroscopic manipulation follows for selected migrated catheters, and laparoscopic revision is reserved for structural problems. Their sharpest point is that a catheter repositioned on X-ray may still fail if omental wrap, adhesions or fixed kinking are present. That echoes the meta-analysis: fixation prevents migration, but migration is only one mechanism among several. Their support for same-session removal and reinsertion rests on observational series. They frame success as rapid return to the prescribed regimen with minimal temporary haemodialysis, not radiographic position.
Written by AI from the published abstract, for healthcare professionals. Not medical advice; check the paper before acting on it.
- 05
Risk factors for subsequent recurrent, relapsing, and repeat peritonitis in peritoneal dialysis.
Among 275 peritonitis episodes, ineffective initial or delayed adequate antibiotic therapy predicted subsequent relapsing or repeat peritonitis, and diabetes also raised odds of recurrent, relapsing or repeat episodes.
Clinical kidney journal · 2026
From the briefingPeritonitis remains the main driver of catheter loss and transfer, and three papers address who gets it again and who loses the catheter. In the Clinical Kidney Journal, Shih and colleagues analysed sixteen years of episodes at their programme [5]. They included 275 episodes from 152 patients who stayed on dialysis afterwards. For any recurrent, relapsing or repeat episode, the associated factors were diabetes, an index episode that was itself a repeat phenotype, and female sex. Fewer automated treatment days and a heavier manual exchange burden also carried higher odds. The authors are candid that those two prescription measures mirror each other, and neither survived mutual adjustment. The analysis cannot say whether automated dialysis protects or whether it is simply a marker of something else. For relapse and repeat episodes specifically, the modifiable signal was antibiotic management. Ineffective initial therapy and delays in adequate therapy were associated with higher odds, whereas the organism group and acute severity markers were not. This is a single-programme cohort with modest event numbers, but the antibiotic finding has clear plausibility.
Written by AI from the published abstract, for healthcare professionals. Not medical advice; check the paper before acting on it.
- 06
The relationship between the rate of decline in residual kidney function and technique failure in patients undergoing peritoneal dialysis: a retrospective cohort study.
In 539 PD patients, faster residual kidney function decline independently raised technique failure risk (HR 1.19 per 0.1 ml/min/1.73 m2/month), with a candidate threshold at -0.20 requiring external validation.
BMC Nephrology · 2026
From the briefingMoving to long-term prognosis, two cohorts look at signals clinicians already measure but may not act on. In BMC Nephrology, Xu and colleagues followed 539 patients at a single centre for a median of thirty months [6]. They examined whether the slope of residual kidney function decline, rather than its level, predicts technique failure. Faster decline was independently associated with failure, at roughly a fifth more risk for each 0.1 increment in monthly loss. The relationship was nonlinear, with a candidate threshold of minus 0.20 millilitres per minute per month. Patients declining faster than that threshold fared measurably worse. Two cautions apply. Technique failure here includes death, so the composite blends dialysis failure with mortality. A threshold derived from a spline in one cohort is exactly the kind of number that shrinks or moves on external validation, which the authors acknowledge is needed.
Written by AI from the published abstract, for healthcare professionals. Not medical advice; check the paper before acting on it.
- 07
Global Evolution of Microbiological Patterns and Pharmacological Guidance in the Management of Peritoneal Dialysis-Associated Peritonitis: An Evolution of Epidemiology and Clinical Practice.
Gram-positive organisms still predominate in PD peritonitis, but regional rises in Gram-negative, fungal and resistant organisms challenge empirical regimens and support programme-specific surveillance and individualised intraperitoneal therapy.
Pathogens · 2026
From the briefingThat point about getting empirical therapy right is the spine of a narrative review in Pathogens from Suliman and colleagues [7]. Gram-positive organisms still dominate in most programmes. The review documents rising Gram-negative, polymicrobial, fungal and culture-negative infections in some regions, alongside resistant organisms from methicillin-resistant staphylococci to multidrug-resistant non-fermenters. The authors trace a shift from standard empirical combinations toward individualised therapy informed by local susceptibility, pharmacokinetics and drug monitoring. They flag that optimal dosing in automated dialysis remains poorly evidenced. Read together, the cohort and the review converge. If inadequate initial antibiotics predict the next episode, then programme-level microbiology surveillance becomes part of recurrence prevention. Neither paper tests that link directly.
Written by AI from the published abstract, for healthcare professionals. Not medical advice; check the paper before acting on it.
- 08
Neutrophil-to-lymphocyte ratio combined with serum albumin predicts catheter removal in patients with peritoneal dialysis-associated peritonitis: a retrospective cohort study of 156 cases.
Among 156 peritonitis patients, 35 needed catheter removal; higher NLR and lower albumin predicted removal, and the combined model was internally validated but needs external validation.
American journal of translational research · 2026
From the briefingOn the question of who loses the catheter, Peng and colleagues, in the American Journal of Translational Research, built a simple model from two routine bloods drawn within a day of onset [8]. Those markers were the neutrophil-to-lymphocyte ratio and serum albumin. Among 156 patients, 35 had their catheter removed. A higher ratio and lower albumin each tracked with removal, and the combination outperformed either marker alone with acceptable discrimination after internal resampling. With only thirty-five events, a retrospective single-centre design and no external validation, the authors themselves say it is not ready for clinical use.
Written by AI from the published abstract, for healthcare professionals. Not medical advice; check the paper before acting on it.
- 09
Patient Perspectives on Their Home Peritoneal Dialysis Experience: A Qualitative Study.
Interviews with 31 PD patients found treatment experience shaped by desire for normalcy, freedom and independence, technical and home-logistics demands, and symptom relief, suggesting modifiable targets in technique, logistics and support.
Kidney360 · 2026
From the briefingSet against that, Hsu and colleagues in Kidney360 interviewed 31 current and former patients in the United States [9]. They found experiences that varied enormously. Patients valued normalcy, freedom and independence, but defined each differently. Technical demands and home logistics shaped whether those goals were met, and symptom relief was highly prized. The tension with the economic model is real. The model treats the benefit of peritoneal dialysis as an average applied to everyone, while the interviews suggest the benefit depends on support, logistics and technical burden that differ person to person. A pragmatic study linking the modifiable care factors these interviews identify to technique survival and quality of life would show how much of the modelled advantage holds when uptake is pushed. A small qualitative sample cannot do that on its own.
Written by AI from the published abstract, for healthcare professionals. Not medical advice; check the paper before acting on it.
- 10
Association of alkaline phosphatase with mortality in patients on peritoneal dialysis.
In 1,108 incident PD patients, each 1-SD higher ALP was associated with 23% higher all-cause and 64% higher cardiovascular mortality, supporting ALP as a prognostic marker.
Kidney research and clinical practice · 2026
From the briefingIn Kidney Research and Clinical Practice, Kim and colleagues examined alkaline phosphatase at dialysis start in 1,108 incident patients over two decades [10]. Higher levels were associated with higher all-cause mortality, about a quarter higher per standard deviation. Cardiovascular mortality rose about two thirds per standard deviation. Patients in the top third of the distribution carried around forty percent higher all-cause risk than those in the lowest third, and the pattern held when the marker was tracked over time. This is a retrospective cohort, and the abstract does not separate bone-specific from liver-derived enzyme. The finding marks a prognostic signal, not evidence that lowering the level changes outcomes.
Written by AI from the published abstract, for healthcare professionals. Not medical advice; check the paper before acting on it.
The full briefing
This AudioScholar briefing is generated by artificial intelligence for healthcare professionals and trainees. It is not medical advice.
Welcome to your bi-weekly update in Peritoneal Dialysis. This period's papers concentrate on the first ninety days of access: when to place the catheter, whether to anchor it, and how to rescue it when flow fails. There is also a cluster on peritonitis, covering what predicts a second episode, which organisms are shifting, and who is likely to lose the catheter. Two cohorts look at long-run prognosis through residual kidney function and an overlooked bone marker. Finally, an economic model makes a strong case for starting on peritoneal dialysis, and a qualitative study complicates that case from the patient's side.
Catheter access is where most early technique failure begins, and three papers this period look at it from insertion through to salvage. The most provocative is a North American registry analysis in the American Journal of Kidney Diseases from Dhoot and colleagues [1]. They asked whether symptom-driven dialysis initiation, which current guidelines endorse, leaves patients getting catheters too late and starting too soon. Among 1,537 catheter insertions, about two thirds of patients had an eGFR of 9 or below at placement. The headline comparison was flat: early complications ran at roughly a fifth in both groups, with no statistically significant difference. Within the lower-function group, though, each one-point drop in eGFR carried about a ten percent higher complication risk. Starting dialysis within thirty days of insertion roughly tripled the risk of complications, which were mostly flow problems, leaks and pain. Conversion to haemodialysis did not differ. There is an internal tension here. The dichotomous comparison found nothing, and the signal emerges only in a continuous within-group model. The design is retrospective, the eGFR values were not standardized, function was not measured at actual dialysis start, and pre-dialysis care and embedded catheters were not accounted for. The authors read this as support for earlier insertion and a longer break-in period. The evidence is observational and hypothesis-generating rather than settled, and it sits awkwardly against guidance that has not changed.
Once the catheter goes in, a meta-analysis in Medicine from Tang and colleagues asks whether fixing it in place during open surgery is worth the effort [3]. Across thirteen studies and about 1,275 patients, fixation cut the odds of catheter displacement by more than ninety percent. It did so without measurably increasing infection, bleeding, hernia, infusion pain or omental wrapping, at a cost of about four extra minutes of operating time. Fixation did nothing for malfunction without displacement, which matters. The authors conclude fixation is safe and effective. Several of the pooled outcomes rest on very few events, however, and the included studies appear to be largely smaller trials and cohorts of variable quality, so the displacement finding is the robust part.
That distinction between position and function is exactly where a review in Current Opinion in Nephrology and Hypertension, by McMonagle and Jain, picks up [4]. They argue that dysfunction is too often handled as generic access failure when the response should follow the mechanism. Their sequence starts with excluding infection and acute abdominal pathology, then treating constipation and fibrin, with early abdominal radiography. Fluoroscopic manipulation follows for selected migrated catheters, and laparoscopic revision is reserved for structural problems. Their sharpest point is that a catheter repositioned on X-ray may still fail if omental wrap, adhesions or fixed kinking are present. That echoes the meta-analysis: fixation prevents migration, but migration is only one mechanism among several. Their support for same-session removal and reinsertion rests on observational series. They frame success as rapid return to the prescribed regimen with minimal temporary haemodialysis, not radiographic position.
Peritonitis remains the main driver of catheter loss and transfer, and three papers address who gets it again and who loses the catheter. In the Clinical Kidney Journal, Shih and colleagues analysed sixteen years of episodes at their programme [5]. They included 275 episodes from 152 patients who stayed on dialysis afterwards. For any recurrent, relapsing or repeat episode, the associated factors were diabetes, an index episode that was itself a repeat phenotype, and female sex. Fewer automated treatment days and a heavier manual exchange burden also carried higher odds. The authors are candid that those two prescription measures mirror each other, and neither survived mutual adjustment. The analysis cannot say whether automated dialysis protects or whether it is simply a marker of something else. For relapse and repeat episodes specifically, the modifiable signal was antibiotic management. Ineffective initial therapy and delays in adequate therapy were associated with higher odds, whereas the organism group and acute severity markers were not. This is a single-programme cohort with modest event numbers, but the antibiotic finding has clear plausibility.
That point about getting empirical therapy right is the spine of a narrative review in Pathogens from Suliman and colleagues [7]. Gram-positive organisms still dominate in most programmes. The review documents rising Gram-negative, polymicrobial, fungal and culture-negative infections in some regions, alongside resistant organisms from methicillin-resistant staphylococci to multidrug-resistant non-fermenters. The authors trace a shift from standard empirical combinations toward individualised therapy informed by local susceptibility, pharmacokinetics and drug monitoring. They flag that optimal dosing in automated dialysis remains poorly evidenced. Read together, the cohort and the review converge. If inadequate initial antibiotics predict the next episode, then programme-level microbiology surveillance becomes part of recurrence prevention. Neither paper tests that link directly.
On the question of who loses the catheter, Peng and colleagues, in the American Journal of Translational Research, built a simple model from two routine bloods drawn within a day of onset [8]. Those markers were the neutrophil-to-lymphocyte ratio and serum albumin. Among 156 patients, 35 had their catheter removed. A higher ratio and lower albumin each tracked with removal, and the combination outperformed either marker alone with acceptable discrimination after internal resampling. With only thirty-five events, a retrospective single-centre design and no external validation, the authors themselves say it is not ready for clinical use.
Moving to long-term prognosis, two cohorts look at signals clinicians already measure but may not act on. In BMC Nephrology, Xu and colleagues followed 539 patients at a single centre for a median of thirty months [6]. They examined whether the slope of residual kidney function decline, rather than its level, predicts technique failure. Faster decline was independently associated with failure, at roughly a fifth more risk for each 0.1 increment in monthly loss. The relationship was nonlinear, with a candidate threshold of minus 0.20 millilitres per minute per month. Patients declining faster than that threshold fared measurably worse. Two cautions apply. Technique failure here includes death, so the composite blends dialysis failure with mortality. A threshold derived from a spline in one cohort is exactly the kind of number that shrinks or moves on external validation, which the authors acknowledge is needed.
In Kidney Research and Clinical Practice, Kim and colleagues examined alkaline phosphatase at dialysis start in 1,108 incident patients over two decades [10]. Higher levels were associated with higher all-cause mortality, about a quarter higher per standard deviation. Cardiovascular mortality rose about two thirds per standard deviation. Patients in the top third of the distribution carried around forty percent higher all-cause risk than those in the lowest third, and the pattern held when the marker was tracked over time. This is a retrospective cohort, and the abstract does not separate bone-specific from liver-derived enzyme. The finding marks a prognostic signal, not evidence that lowering the level changes outcomes.
Finally, two papers approach the choice of peritoneal dialysis itself, one from the health system and one from the patient's chair, and they do not tell the same story. In PharmacoEconomics Open, Li and colleagues modelled lifetime outcomes for incident patients in the United Kingdom National Health Service [2]. Starting on peritoneal dialysis rather than in-centre haemodialysis gained a small amount of quality-adjusted life and saved roughly twenty thousand pounds per patient. That makes it dominant across sensitivity analyses. Their budget model projected savings of about 220 million pounds over five years if prevalence reached twenty percent. This is a Markov model built on registry data, so its conclusions inherit the selection that shapes who currently receives peritoneal dialysis. The abstract does not describe funding or conflicts of interest, which matters for an analysis of this kind.
Set against that, Hsu and colleagues in Kidney360 interviewed 31 current and former patients in the United States [9]. They found experiences that varied enormously. Patients valued normalcy, freedom and independence, but defined each differently. Technical demands and home logistics shaped whether those goals were met, and symptom relief was highly prized. The tension with the economic model is real. The model treats the benefit of peritoneal dialysis as an average applied to everyone, while the interviews suggest the benefit depends on support, logistics and technical burden that differ person to person. A pragmatic study linking the modifiable care factors these interviews identify to technique survival and quality of life would show how much of the modelled advantage holds when uptake is pushed. A small qualitative sample cannot do that on its own.
If you read only one paper from this period, make it the North American registry study from Dhoot and colleagues on eGFR at catheter insertion. It reopens a question most programmes treat as settled: whether symptom-driven initiation, applied across modalities, costs peritoneal dialysis patients a safe break-in period.
Here is what this period adds up to. First, the timing of access is coming back into question. Observational data now link lower kidney function at insertion and short break-in periods to early complications, but no trial has tested earlier insertion. Second, catheter fixation in open surgery has solid support for preventing migration, while the dysfunction literature makes clear that migration is only one mechanism, and repositioning alone does not guarantee function. Third, in peritonitis, the most consistent modifiable thread is antibiotic adequacy, tying recurrence risk to local resistance surveillance, though the evidence is single-centre and associational. Fourth, residual function slope and alkaline phosphatase both emerge as prognostic markers, neither externally validated as a trigger for intervention. And watch the gap between system-level economics and individual experience. The case for expanding peritoneal dialysis is strong on paper, but whether it survives contact with real patients' homes is still unsettled.
That's your Peritoneal Dialysis update for this period. Until next time.
This is an automated summary generated by artificial intelligence, which can make mistakes. Always review the original source materials.
Spot something worth flagging?
Get this every week in your podcast app — free.
New research episodes land in your feed automatically — listen on your commute.